The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa

Mov Disord. 2000 Sep;15(5):1016-7. doi: 10.1002/1531-8257(200009)15:5<1016::aid-mds1042>3.0.co;2-j.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiparkinson Agents / pharmacology*
  • Antiparkinson Agents / therapeutic use
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / etiology
  • Dyskinesia, Drug-Induced / prevention & control*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Humans
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Memantine / administration & dosage
  • Memantine / therapeutic use*
  • N-Methylaspartate / antagonists & inhibitors*
  • Parkinsonian Disorders / complications
  • Parkinsonian Disorders / drug therapy*
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Excitatory Amino Acid Antagonists
  • Levodopa
  • N-Methylaspartate
  • Memantine